Patents by Inventor Eugen Proschak

Eugen Proschak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • N-PHENYL-3-MERCAPTOPROPANAMIDE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS FOR THE TREATMENT OF BACTERIAL INFECTIONS
    Publication number: 20230146507
    Abstract: The present invention related to novel inhibitors of metallo-?3-lactamases of formula (I) wherein R1 is an optionally substituted aryl group of an optionally substituted heteroaryl group, and the use thereof in the treatment of bacterial infections, especially in combination with ?-lactam antibiotics.
    Type: Application
    Filed: March 23, 2021
    Publication date: May 11, 2023
    Inventors: Rolf W. Hartmann, Jelena Konstantinovic, Jörg Haupenthal, Anna K. Hirsch, Andreas M. Kany, Cansu Kaya, Samir Yahiaoui, Thomas Wichelhaus, Eugen Proschak
  • Orally available sEH/PDE4 dual inhibitors
    Patent number: 11572347
    Abstract: Provided herein are novel bioavailable dual inhibitors capable of inhibiting both soluble epoxide hydrolase (sEH) and phosphodiesterase 4 (PDE4), and methods of using the same.
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: February 7, 2023
    Assignees: The Regents of the University of California, Goethe-University Frankfurt
    Inventors: Bruce D. Hammock, Rene Bloecher, Christophe Morisseau, Yang Kevin Xiang, Karen Wagner, Todd Harris, Raghavender Reddy Gopireddy, Eugen Proschak
  • Diabetes and metabolic syndrome treatment with a novel dual modulator of soluble epoxide hydrolase and peroxisome proliferator-activated receptors
    Patent number: 11447445
    Abstract: N-benzylbenzamides that act as dual soluble epoxide hydrolase (sEH)/peroxisome proliferator-activated receptor ? (PPAR?) modulators and are useful as medications in the treatment of Metabolic Syndrome (MetS) cluster diseases, including diabetes. Methods of making and using the same are further provided.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: September 20, 2022
    Assignees: The Medical College of Wisconsin, Inc., Johann Wolfgang Goethe-Universität Frankfurt
    Inventors: John David Imig, Md. Abdul Hye Khan, Eugen Proschak, Rene Blocher
  • ORALLY AVAILABLE SEH/PDE4 DUAL INHIBITORS
    Publication number: 20210395202
    Abstract: Provided herein are novel bioavailable dual inhibitors capable of inhibiting both soluble epoxide hydrolase (sEH) and phosphodiesterase 4 (PDE4), and methods of using the same.
    Type: Application
    Filed: October 18, 2018
    Publication date: December 23, 2021
    Inventors: Bruce D. HAMMOCK, Rene BLOECHER, Christophe MORISSEAU, Yang Kevin XIANG, Karen WAGNER, Todd HARRIS, Raghavender Reddy GOPIREDDY, Eugen PROSCHAK
  • Diabetes and Metabolic Syndrome Treatment with a Novel Dual Modulator of Soluble Epoxide Hydrolase and Peroxisome Proliferator-Activated Receptors
    Publication number: 20210238125
    Abstract: N-benzylbenzamides that act as dual soluble epoxide hydrolase (sEH)/peroxisome proliferator-activated receptor ? (PPAR?) modulators and are useful as medications in the treatment of Metabolic Syndrome (MetS) cluster diseases, including diabetes. Methods of making and using the same are further provided.
    Type: Application
    Filed: December 23, 2020
    Publication date: August 5, 2021
    Applicants: The Medical College of Wisconsin, Inc., Johann Wolfgang Goethe-Universität Frankfurt
    Inventors: John David Imig, Md. Abdul Hye Khan, Eugen Proschak, Rene Blocher
  • Diabetes and metabolic syndrome treatment with a novel dual modulator of soluble epoxide hydrolase and peroxisome proliferator-activated receptors
    Patent number: 10927069
    Abstract: N-benzylbenzamides that act as dual soluble soluble epoxide hydrolase (sEH)/peroxisome proliferator-activated receptor ? (PPAR?) modulators and are useful as medications in the treatment of Metabolic Syndrome (MetS) cluster diseases, including diabetes. Methods of making and using the same are further provided.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: February 23, 2021
    Assignees: The Medical College of Wisconsin, Inc., Johann Wolfgang Goethe-Universitat Frankfurt
    Inventors: John David Imig, Md. Abdul Hye Khan, Eugen Proschak, Rene Blocher
  • Diabetes and Metabolic Syndrome Treatment with a Novel Dual Modulator of Soluble Epoxide Hydrolase and Peroxisome Proliferator-Activated Receptors
    Publication number: 20180297936
    Abstract: A catheter assembly includes an elongated catheter shaft, a magnetic sensor, and one or more wires. The elongated catheter shaft has a shaft proximal end and a shaft distal end, and the magnetic sensor includes a coil having a coil proximal end and a coil distal end that is situated toward or at the shaft distal end. The one or more wires extend through the elongated catheter shaft and are situated adjacent the magnetic sensor. Each of the one or more wires is electrically coupled to the coil at the coil distal end.
    Type: Application
    Filed: July 1, 2016
    Publication date: October 18, 2018
    Applicants: The Medical College of Wisconsin, Inc., Johann Wolfgang Goethe-Universität Frankfurt
    Inventors: John David Imig, Md. Abdul Hye Khan, Eugen Proschak, Rene Blocher